Drug Profile

COYA 303

Alternative Names: COY303; COYA 301 + GLP-1 receptor agonist - Coya Therapeutics; COYA-303

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Coya Therapeutics
Class Anti-inflammatories; Interleukins
Mechanism of Action Glucagon-like peptide-1 receptor agonists; Interleukin 2 replacements; Regulatory T-lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

18 Mar 2025 COYA 303 is available for licensing as of 18 Mar 2025. https://coyatherapeutics.com/
18 Mar 2025 Preclinical trials in Inflammation in USA (SC) (Coya Therapeutics pipeline; March 2025)
06 Nov 2024 Coya Therapeutics files for patent protection for COYA 301 and GLP-1 receptor agonist combination

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com